1. Medtech Insight
  2. >>Policy & Regulation

Advances In Reimbursement: Prostate Cancer AI Mapping Receives CPT Code

 
• By Hannah Daniel

Avenda’s chief operating officer Brit Berry-Pusey spoke to Medtech Insight about the company’s CPT III code for its prostate cancer mapping AI and how regulatory bodies can align to support innovators.

• Source: Shutterstock

Medtech Insight speaks with industry experts about trends and innovations with potential to transform cancer care.

Avenda Health’s Current Procedural Terminology code for its prostate cancer-mapping artificial intelligence device went into effect in July, moving the needle forward for AI reimbursement in cancer treatment.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Policy & Regulation

More from Medtech Insight

Get Ready For International Harmonization Before Approaching QMSR Deadline, Says Regulatory Expert

 
• By Brian Bossetta

During MD&M East last week, regulatory consultant Darren Reeves reminded device manufacturers that the time to get ready to comply with the new Quality Management System Regulation is now.

Handheld Diagnostics: A Resurging Category That is Here to Stay

 
• By Barnaby Pickering

Handheld diagnostics are more powerful, accessible and clinically relevant than ever. Medtech Insight spoke to companies behind such technologies to learn how they work and discuss their commercial models.

Execs On The Move: 12-23 May 2025

 
• By Medtech Insight Team

An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.